Metzger Michael A's Form 4 filing
Cti Biopharma Corp (CTIC) · filed Jul 7, 2022
- Accession no.
- 0000891293-22-000035
- Filed
- Jul 7, 2022
- Trade date
- Jul 5, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $556.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2022 | common stock | MOption exerciseAcquired | +91,500 | $0.84 | +$76,860 | 111,621 | Direct | |
| Jul 5, 2022 | common stock | SSaleDisposed | −8,700 | $5.98F2 | −$52,026 | 102,921 | Direct | |
| Jul 5, 2022 | common stock | SSaleDisposed | −51,963 | $6.05F3 | −$314,376.15 | 50,958 | Direct | |
| Jul 5, 2022 | common stock | SSaleDisposed | −27,506 | $6.14F4 | −$168,886.84 | 23,452 | Direct | |
| Jul 5, 2022 | common stock | SSaleDisposed | −3,331 | $6.23F5 | −$20,752.13 | 20,121 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2022 | Common Stock | MOption exerciseDisposed | −91,500 | $0.00 | $0 | 28,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.95 to $ 5.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.00 to $ 6.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.11 to $ 6.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F5
Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.21 to $ 6.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.